Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma
NCT03922984 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43
Last updated 2024-10-22
Summary
MRI including ASL will be performed before, during and after the treatment, in a total of 7 MRI sessions until 8 months after the first session. Thereafter, patients will be followed through standard clinical examinations for the next 3 years or until demise, whichever occurs first.
Clinically, GBM patients are imaged every 8-weeks, beginning at 10 weeks after the completion of chemoradiation, since morphological (i.e. size) changes are not anticipated earlier. However, our preliminary experience and others have shown functional changes including perfusion and diffusion as early as 3-weeks after the initiation of the treatment . Thus, our T10, T18, T26 and T34 MRI sessions will be performed along with the clinical imaging sessions, while the T3 and T6 MRI sessions will be performed additionally for this proposal. All MR imaging sessions will be scheduled within ±1 or ±2 weeks of the target time period, as indicated in the table.
MRI including ASL will be performed before, during and after the treatment, in a total of 7 MRI sessions until 8 months after the first session. The research MR imaging may take approximately an additional 15 minutes per each imaging session. However, the T3, and T6 MR imaging sessions will be performed additionally for the purpose of this study, with each taking approximately one hour. Thereafter, patients will be followed through standard clinical examinations for the next 3 years or until demise, whichever occurs first.
Conditions
Interventions
- PROCEDURE
-
MRI with Arterial Spin Labeling (ASL)
Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
University of Texas Southwestern Medical Center
lead OTHER
Principal Investigators
-
Ananth Madhuranthakam, PhD · UT Southwestern Medical Center
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-04-16
- Primary Completion
- 2024-01-22
- Completion
- 2024-01-22
Countries
- United States
Study Locations
More Related Trials
-
Measuring Non-Enhancing Glioblastoma Progression
NCT00777686 ·Status: COMPLETED
-
Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors
NCT00005790 ·Status: WITHDRAWN ·Phase: NA
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
NCT00870129 ·Status: RECRUITING ·Phase: NA
-
Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma
NCT01880008 ·Status: COMPLETED
-
Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma
NCT01018329 ·Status: COMPLETED ·Phase: NA
-
Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
NCT02731521 ·Status: COMPLETED
-
68Ga-citrate PET/MR Imaging for Glioma
NCT03335280 ·Status: TERMINATED
-
Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma
NCT00005082 ·Status: COMPLETED ·Phase: NA
-
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
NCT01604590 ·Status: COMPLETED
-
Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma
NCT04143425 ·Status: COMPLETED
-
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
NCT06090903 ·Status: RECRUITING ·Phase: NA
-
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
NCT04265430 ·Status: RECRUITING ·Phase: PHASE4
-
MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer
NCT00984074 ·Status: COMPLETED
-
Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma
NCT06183983 ·Status: RECRUITING ·Phase: NA
-
Study on Neuroepithelial Tumor Grading and Pseudoprogression After Glioma Therapy Using Advanced Functional MRI Techniques
NCT02622620 ·Status: UNKNOWN
-
Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma
NCT03439332 ·Status: COMPLETED
-
Response Assessment During MR-guided Radiation Therapy for Glioblastoma
NCT05565326 ·Status: RECRUITING
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
NCT04699773 ·Status: RECRUITING ·Phase: NA
-
Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas
NCT03542409 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Evaluating Tumor Pseudoprogression With FLT-PET and MRI
NCT01105988 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas
NCT03180697 ·Status: UNKNOWN
-
Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme
NCT01252459 ·Status: UNKNOWN ·Phase: PHASE2
-
Brain Glioma Registry Combining Clinical and Imaging Information
NCT02619890 ·Status: RECRUITING
-
Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas
NCT02379572 ·Status: COMPLETED ·Phase: NA
-
MRI in High-Grade Glioma Patients Undergoing Chemoradiation
NCT05212272 ·Status: RECRUITING ·Phase: NA